IGHD3-10: A Potential Drug Target and Biomarker (G28499)

Target Name: IGHD3-10

NCBI ID: G28499

IGHD3-10

Other Name(s): IGHD310 | immunoglobulin heavy diversity 3-10 | DXP'1 | Immunoglobulin heavy diversity 3-10

IGHD3-10: A Potential Drug Target and Biomarker

The IGHD3 gene is a non-coding RNA molecule that is part of the intergenic region on chromosome 11. It is a key regulator of the immune response and has been implicated in various diseases, including immune-related disorders and neurodegenerative diseases. The IGHD3 gene has three splice variants, IGHD3-10, IGHD3-2, and IGHD3-3, which differ in their last exon. IGHD3-10 is the most abundant splice variant and is expressed in most tissues of the body.

In recent years, researchers have identified IGHD3-10 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGHD3-10 has also been shown to play a role in the regulation of cellular processes that are important for human health, such as inflammation, stress responses, and cellular signaling.

Drug Target Potential

IGHD3-10 has been identified as a potential drug target due to its involvement in the regulation of immune responses and its expression in various tissues of the body. IGHD3-10 has been shown to play a role in the regulation of T cell development and function, as well as in the regulation of inflammation and cellular signaling.

One of the key activities of IGHD3-10 is its regulation of the cytokine profile of T cells. IGHD3-10 has been shown to play a role in the regulation of the cytokine profile of T cells, which is important for their ability to recognize and respond to various antigens. IGHD3-10 has also been shown to regulate the production of Th2 cytokines, which are important for the regulation of inflammation and tissue repair.

In addition to its role in T cell regulation, IGHD3-10 has also been shown to play a role in the regulation of inflammation. IGHD3-10 has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6. It has also been shown to regulate the expression of anti-inflammatory cytokines, such as IL-10 and IL-12.

Biomarker Potential

IGHD3-10 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGHD3-10 has been shown to have potential as a biomarker for cancer, as it has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancers.

IGHD3-10 has also been shown to have potential as a biomarker for neurodegenerative diseases, as it has been shown to be downregulated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, IGHD3-10 has been shown to have potential as a biomarker for autoimmune disorders, as it has been shown to be downregulated in various autoimmune disorders, including rheumatoid arthritis, Crohn's disease, and multiple sclerosis.

Conclusion

IGHD3-10 is a non-coding RNA molecule that has been shown to play a role in the regulation of various immune and cellular processes in the body. Its expression and regulation have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target and biomarker, IGHD3-10 is a promising target for the development of new therapies for these diseases. Further research is needed to fully understand the role of IGHD3-10 in the regulation of immune and cellular processes and its potential as a drug target and biomarker.

Protein Name: Immunoglobulin Heavy Diversity 3-10

The "IGHD3-10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHD3-10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets